Clinical Trial Update: Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of delanzomib (CEP-18770) in relapsed/refractory multiple myeloma has been terminated before completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Delanzomib (delanzomib)

Snippet

Sponsor: Cephalon | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED